119 results
8-K
EX-99.1
BTAI
BioXcel Therapeutics Inc
9 May 24
BioXcel Therapeutics Reports First Quarter 2024 Financial Results
7:12am
to evaluate the efficacy and safety of a 60 mcg dose of BXCL501 for agitation associated with Alzheimer’s dementia (AAD).
SERENITY At-Home* safety trial … : designed to evaluate the safety of a 120 mcg dose of BXCL501 in the at-home setting for agitation associated with bipolar disorders or schizophrenia
8-K
EX-99.1
BTAI
BioXcel Therapeutics Inc
22 Apr 24
Regulation FD Disclosure
7:10am
be considered forward - looking statements, including, without limitation, statements related to the safety, efficacy, and regulatory and clinical design … clinical data supporting potential safety or efficacy of BXCL 501 for use in the at - home setting ; its dependence on the success and commercialization
8-K
BTAI
BioXcel Therapeutics Inc
22 Apr 24
Regulation FD Disclosure
7:10am
as a double blind, placebo-controlled study to evaluate the safety and efficacy of a 120 mcg dose of BXCL501 over a 12-week period.
The outpatient … -administer 120 mcg of BXCL501 or placebo when agitation episodes occur over the trial period.
The primary objective is safety with efficacy measures
8-K
BTAI
BioXcel Therapeutics Inc
10 Apr 24
Regulation FD Disclosure
7:05am
blind, placebo-controlled study to evaluate the efficacy and safety of a 60 mcg dose of BXCL501 over a 12-week period.
The trial is expected … Phase 3 efficacy and safety data in the TRANQUILITY In-Care trial to expand the database beyond the 70 patients who have already been treated with 60
8-K
EX-99.1
2irn7w57qvque uj54
10 Apr 24
Regulation FD Disclosure
7:05am
8-K
EX-10.1
94g14gytoa0 niun
25 Mar 24
Entry into a Material Definitive Agreement
4:05pm
8-K
EX-99.1
3844sqf
12 Mar 24
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
7:15am
8-K
EX-99.1
dk75 ws3w
14 Feb 24
Regulation FD Disclosure
7:00am
424B5
f5v3rvh33suyrbjv
8 Feb 24
Prospectus supplement for primary offering
5:27pm
8-K
xamv5
8 Feb 24
Other Events
4:53pm
8-K
EX-10.1
t1ih9v2f07gojlpc0p
8 Feb 24
Other Events
4:53pm
8-K
1xz1 i54ayi
12 Dec 23
Other Events
7:00am
424B5
q9dmoe8 hk3v7j0cfg
14 Nov 23
Prospectus supplement for primary offering
8:57am
8-K
EX-99.1
qnr6ch sp
14 Nov 23
Results of Operations and Financial Condition
12:00am
8-K
EX-99.1
na50ai0
10 Oct 23
Regulation FD Disclosure
7:06am